Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04625699
Title Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Catherine Shu

lung non-small cell carcinoma


Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST